CPT® Code 91315

Deleted

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

The CPT® Code 91315 refers to a specific formulation of the COVID-19 vaccine designed to provide immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the disease known as COVID-19. This vaccine utilizes a bivalent approach, meaning it contains messenger RNA (mRNA) components that correspond to both the original strain of the virus and the omicron variant, specifically targeting the BA.4 and BA.5 subvariant lineages. The vaccine is preservative-free and is delivered in a dosage of 10 mcg per 0.2 mL, which is suitable for intramuscular administration. The mRNA is encapsulated in lipid nanoparticles (mRNA-LNP), allowing for effective delivery into the body's cells. Upon administration, the cells utilize the mRNA to produce the viral spike protein, which is recognized by the immune system as foreign, prompting the production of antibodies. This immune response is crucial for protecting individuals from severe illness upon exposure to the virus. The vaccine is specifically indicated for children aged 5 through 11 years who have previously received COVID-19 vaccinations. It is important to note that the preparation of this vaccine involves diluting it with preservative-free normal saline to achieve the correct dosage for pediatric patients. The TRIS-sucrose formulation includes buffering agents that help stabilize the vaccine and maintain its pH, ensuring its efficacy and safety when administered.